Isunakinra is under clinical development by Buzzard Pharmaceuticals and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Isunakinra’s likelihood of approval (LoA) and phase transition for Solid Tumor took place on 19 Aug 2021, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Isunakinra Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Isunakinra overview

Isunakinra (EBI-005) was under development for the treatment of moderate to severe allergic conjunctivitis and solid tumors. The drug candidate is administered through ophthalmic route. It acts by targeting interleukin-1 (IL-1) receptor. It is developed based on AMP-Rx protein engineering platform. It was also under development for severe ocular allergy and dry eye disease.

Quick View Isunakinra LOA Data

Report Segments
  • Innovator
Drug Name
  • Isunakinra
Administration Pathway
  • Ophthalmic
Therapeutic Areas
  • Oncology
  • Ophthalmology
Key Developers
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.